about
Kinases as druggable targets in trypanosomatid protozoan parasitesUsing existing drugs as leads for broad spectrum anthelmintics targeting protein kinasesThe susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposingOpen-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseasesA target repurposing approach identifies N-myristoyltransferase as a new candidate drug target in filarial nematodesIdentification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaignMiltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical StudyA Multilayer Network Approach for Guiding Drug Repositioning in Neglected DiseasesDiscovery of a Carbazole-Derived Lead Drug for Human African TrypanosomiasisNew chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugsRepurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitorsEVALUATION OF AROMATIC 6-SUBSTITUTED THIENOPYRIMIDINES AS SCAFFOLDS AGAINST PARASITES THAT CAUSE TRYPANOSOMIASIS, LEISHMANIASIS, AND MALARIA.Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei.Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1)Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 1. Sildenafil analogs.Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs.Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis.Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases.The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.Identification of "Preferred" Human Kinase Inhibitors for Sleeping Sickness Lead Discovery. Are Some Kinases Better than Others for Inhibitor Repurposing?Repurposing strategies for tropical disease drug discovery.Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasisSynthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1).Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015).Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases.Docking to multiple pockets or ligand fields for screening, activity prediction and scaffold hopping.Integrative analysis of ocular complications in atherosclerosis unveils pathway convergence and crosstalk.Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.Cell Cycle Inhibition To Treat Sleeping SicknessEstablishment of a structure-activity relationship of 1H-imidazo[4,5-c]quinoline-based kinase inhibitor NVP-BEZ235 as a lead for African sleeping sickness.Drugs for neglected diseases: part I.An automated high-throughput system for phenotypic screening of chemical libraries on C. elegans and parasitic nematodes.Interview with Future Medicinal Chemistry's US Senior Editor, Iwao Ojima. Interview by Issac Bruce.3D-e-Chem: Structural Cheminformatics Workflows for Computer-Aided Drug Discovery.Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite ProliferationIdentification of levothyroxine antichagasic activity through computer-aided drug repurposing
P2860
Q26786761-8855F386-F750-4FCF-81A9-4FCD65AF4538Q27336465-856975BA-0DF2-47D3-9F98-81D19FEC412FQ28476644-61A5C3E6-4A0C-4013-8104-5A686A36B35EQ28535314-2A9D19B3-B3DD-4CBB-9E63-A347A44BD1C7Q28542766-03AF7663-095A-414F-9C13-F236F37360E3Q28544017-908460E4-5A46-4A1F-92FA-BB5989696AE2Q28551006-C5551A56-8C8B-4969-BA00-3C8D3644009BQ28552140-496A46F7-5AB9-464B-A69A-AFB0F46521BEQ28828834-D24CEB2C-5B63-4207-BA40-0F9DAEAA222BQ33622982-F972D2B4-6268-4A2D-AAFD-190484E89395Q34138086-8BFDBF3D-802C-41F7-98D9-EAF7FF17DAFCQ35072529-47ACFD89-3414-4BDC-B9A5-1540239050CEQ35270030-09744DA9-523D-4470-A7B6-8140BD84C0DDQ35587147-C935117A-6C93-42D6-A023-19DBFDFC4A43Q35592068-4785407E-F44E-4B4B-A921-2D098AB948A6Q35840120-5F293083-6F29-41C3-A2E3-DB900E59F41EQ35840481-9B53D72F-553F-4E83-891E-207279C84C39Q35891268-1CD7508C-28D8-45B5-AE15-0BE5B4DE2D0BQ36298245-47354452-8B02-4162-8821-D4C2446A7A4BQ36382655-AA844C87-A5D0-4C08-AFEA-51025F3DEA44Q36451580-178868A7-E7FC-4414-B1C0-DD36CEA0E1FAQ36686364-8AFBED40-DAF1-460B-AC32-C45AB2399119Q36858635-869881D3-D1F0-45AC-89B4-D00C34E65C96Q36874745-074B9340-8975-47E9-B461-1E69D9A98236Q37301306-668942F2-A94A-45D7-898F-F99B2E7F3D54Q38845466-358D6B99-36C8-4662-904B-9572EC886B4BQ38972808-C3518FD1-8DF2-4711-9673-84509BFFC8D4Q39096521-737E4392-138A-49BA-AE44-A48EBFB72D35Q39155136-C1F4A67B-98D6-4530-850F-F2E995A2EF5EQ40306944-567A27CF-716F-4D08-9094-47B26E33C97DQ41676261-53788E7B-46CA-4908-BFCA-FDEB3CB21901Q42736573-30F27570-0FF1-4723-86A4-B2300EE28B40Q44544936-A50F2749-D108-474D-9C7E-33566AA748DFQ47177309-CE563C4A-FFAE-458B-B51C-1138603AA2C3Q48409114-5E839DA5-3238-409F-A9BA-9F254CDA76E2Q50029498-1703B696-08EA-40B3-92E5-669ED75A749CQ57822499-DD5B8886-3D92-4DDD-B59C-4D264820FEC4Q59075291-6B8FB418-CF25-427C-B86F-5A89259A68E2
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Target repurposing for neglected diseases.
@ast
Target repurposing for neglected diseases.
@en
type
label
Target repurposing for neglected diseases.
@ast
Target repurposing for neglected diseases.
@en
prefLabel
Target repurposing for neglected diseases.
@ast
Target repurposing for neglected diseases.
@en
P2860
P356
P1476
Target repurposing for neglected diseases.
@en
P2093
Robert K Campbell
P2860
P304
P356
10.4155/FMC.11.92
P577
2011-08-01T00:00:00Z